The same group subsequently reported a case study where they observed regression of an IL13Rα2-positive multifocal GBM tumor in a patient treated with intraventricular administrations of second generation IL13Rα2-CAR T-cells that also express CD137 intracellular domain as part of the CAR construct (26). This evidence concerns the gene IL13RA2 and glioblastoma.